Back to results
US 2024/0100139 A1Published application
Neoantigens and uses thereof
AssigneeBiontech US Inc.
InventorVikram Juneja
Life of this patent
Estimating the term…
Abstract
Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.
Claims23
A method of treating cancer in a subject in need thereof, the method comprising:
- (a) administering to the subject a first pharmaceutical composition comprising autologous T cells, wherein the autologous T cells comprise:
- (i) a first plurality of autologous T cells stimulated with antigen presenting cells (APCs) that present a first neoepitope as a complex with a class II HLA protein, wherein the class II HLA protein is a protein encoded by a class II HLA allele of the subject;
- or,
- (ii) a second plurality of autologous T cells stimulated with APCs that present a second neoepitope as a complex with a class I HLA protein, wherein the class I HLA protein is a protein encoded by a class I HLA allele of the subject;
- wherein the first neoepitope and the second neoepitope are from a first protein, and
- wherein the first neoepitope and the second neoepitope comprise the same mutation;
- (b) subsequent to (a), administering to the subject a second pharmaceutical composition comprising one or more polypeptides comprising a neoepitope, or one or more polynucleic acids encoding the one or more polypeptides.
4 more elements
Dependencies are inferred from the claim text.